-
| Exchange | LSE |
|---|---|
| CurrencyCode | GBP |
| ISIN | GB00BMWLM973 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | 34.0 |
|---|---|
| Target Price | 275.5 |
| Beta | -0.21 |
| Market Cap | 26M |
| Dividend Yield | None |
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AREC.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026